Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.62 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.53 |
| ▸ | CCR4 | P51679 | 2/20 | 0.47 |
| ▸ | EDNRB | P24530 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 2/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381363 | 0.95 | HSD11B1 (0.59) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1379502 | 0.95 | HSD11B1 (0.59) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1379109 | 0.84 | HSD11B1 (0.69) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL3926308 | 0.83 | HSD11B1 (0.68) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1375525 | 0.82 | PIK3C3 (0.47) | HSD11B1PIK3C3MAPTMEN1KMT2A | |
| SCHEMBL1378719 | 0.80 | HSD11B1 (0.55) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1381424 | 0.80 | HSD11B1 (0.63) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1380007 | 0.80 | HSD11B1 (0.63) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1381212 | 0.79 | HSD11B1 (0.62) | HSD11B1SLC40A1CCR4EDNRBEDNRA | |
| SCHEMBL1830383 | 0.79 | HSD11B1 (0.53) | HSD11B1SLC40A1CCR4EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4809339-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | claimed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | claimed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | claimed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | claimed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | claimed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | claimed |
| EP-1763517-B1 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010121814-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST | ONTOCHEM GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2243494-A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. | OntoChem GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885SLC40A1 2849/4885CCR4 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.